Novo Nordisk has begun shipping the oral form of semaglutide branded as Wegovy to U.S. pharmacies, prompting immediate questions about pricing and access. The company said prescriptions could be filled immediately for patients with existing scripts, and public reports noted insurers may reduce out‑of‑pocket costs to as low as $25 monthly for covered patients while cash pricing starts at $149 per month for a starter dose. The pill mirrors injectable semaglutide’s mechanism but requires higher oral dosing to match exposure.